10 unknown. 10 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Unknown 10 |
| Phase 1 | 3 | Unknown 3 |
| Phase 3 | 1 | Unknown 1 |
Follow Relapse: new trials by email Literature Review of Relapse trials Research Report on Relapse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma PD-1 inhibitor - Hodgkin Lymphoma, Adult, Relapse | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 47 | 2022-01-01 | 2021-12-17 |
| Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies Ibrutinib Combined With Rituximab - DLBCL, MYD88 Gene Mutation | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 20 | 2021-10-01 | 2021-08-06 |
| Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute Leukemia Sorafenib - Acute Leukemia, Relapse | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 346 | 2020-12-15 | 2021-11-08 |
| Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia Dual target CAR-T cell therapy - Dual-target CAR-T Cells, B ALL | Phase 1 / Phase 2 | Unknown | Shenzhen University General Hospital | 20 | 2020-10-20 | 2021-01-26 |
| Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse Bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination - Epithelial Ovarian Cancer, Relapse | Phase 2 | Unknown | ARCAGY/ GINECO GROUP | 74 | 2019-03-01 | 2022-08-17 |
| Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies Prophylactic DLI - Donor Lymphocyte Infusion, Peripheral Blood Stem Cell Transplantation | Phase 2 | Unknown | Chinese PLA General Hospital | 40 | 2019-01-01 | 2018-12-13 |
| CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia CD19 CAR-T cells, CD19 CAR-T cells with CRS suppression technology - Acute Lymphoblastic Leukemia, CD19 Positive | Phase 1 / Phase 2 | Unknown | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 40 | 2017-07-01 | 2024-05-28 |
| Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant donor lymphocyte infusion - Donor Lymphocyte Infusion, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 | Unknown | Peking University People's Hospital | 40 | 2017-03-01 | 2020-03-10 |
| Chidamide Plus DCAG for Relapsed/Refractory AML Chidamide plus DCAG regimen - AML, Relapse | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 100 | 2016-06-01 | 2018-02-14 |
| Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation Mesenchymal stem cells - Graft-versus-host Disease, Relapse | Phase 2 | Unknown | National Research Center for Hematology, Russia | 70 | 2007-10-01 | 2013-09-13 |
Recurrence (10) · Graft vs Host Disease (3) · Burkitt Lymphoma (1) · Carcinoma, Ovarian Epithelial (1) · Hodgkin Disease (1) · Lymphoma (1) · Neoplasm, Residual (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Disease Attributes (10) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Immune System Diseases (7) · Neoplasms (6) · Neoplasms by Histologic Type (5) · Hemic and Lymphatic Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Lymphoma (2) · Adnexal Diseases (1) · Carcinoma (1) · DNA Virus Infections (1) · Endocrine Gland Neoplasms (1)
Decitabine (2) · Bevacizumab (1) · Drug Therapy (1) · Immune Checkpoint Inhibitors (1) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1) · Rituximab (1) · Sorafenib (1) · durvalumab (1) · olaparib (1)
Chinese PLA General Hospital (2) · ARCAGY/ GINECO GROUP (1) · Chinese Academy of Medical Sciences (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Nanfang Hospital, Southern Medical University (1) · National Research Center for Hematology, Russia (1) · Peking University People's Hospital (1) · Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd (1) · Shenzhen University General Hospital (1)
China (7) · France (1) · Russia (1)
Dehui Zou, Dr. (1) · Elena Parovichnikova, Prof MD PhD (1) · Gilles Freyer (1) · Li Yu, Dr (1) · Li Yu, MD. Ph.D (1) · Li-Xin Wang, MD. Ph.D. (1) · Qifa Liu (1) · Xiao-jun Huang (1) · Xiaowen Tang, PhD (1) · Yuankai Shi, M.D. (1)
PMID 22242033, PMID 32873343, PMID 33235353, PMID 36105799, PMID 36372356